Smad4 缺失与非小细胞肺癌临床参数的相关性：一项观察性队列研究。
Correlation between loss of Smad4 and clinical parameters of non-small cell lung cancer: an observational cohort study.
机构信息
Department of Respiratory and Critical Care Medicine, The First People's Hospital of Lianyungang City, Lianyungang, Jiangsu, China.
出版信息
BMC Pulm Med. 2021 Apr 1;21(1):111. doi: 10.1186/s12890-021-01480-z.
BACKGROUND
SMAD4 has been found to be inactivated to varying degrees in many types of cancer; the purpose of this study was to investigate the correlation between SMAD4 expression in non-small cell lung cancer (NSCLC) and clinical pathological parameters.
METHODS
The serum concentration of SMAD4 was measured by enzyme-linked immunosorbent assay and its histological expression was quantified by immunohistochemistry.
RESULTS
The serum concentration of Smad4 in patients with NSCLC was lower than that in benign lung disease patients and healthy individuals (P < 0.001) and its concentration was related to the histological classification, pathological differentiation, lymphatic metastasis and clinical stage of NSCLC. The sensitivity and specificity of serum Smad4 were 91.56% and 61.56% for screening NSCLC from healthy individuals and 84.55% and 60.36% for screening NSCLC from patients with benign lung disease. Logistic regression analysis showed that the degree of cell differentiation (P < 0.001), lymph node metastasis (P < 0.001) and clinical stage of NSCLC (P = 0.007) affected the expression of Smad4, and had a strong correlation with the expression of Smad4. The expression of Smad4 in NSCLC tissues was lower than that in normal lung tissues (P = 0.009) and its expression was related to the degree of tissue differentiation, lymph node metastasis and clinical stage (P < 0.05).
CONCLUSIONS
The downregulation or deletion of Smad4 is related to the malignant biological behavior of NSCLC and serum Smad4 could be considered as a potential molecular indicator for diagnosis and evaluation of NSCLC.
背景
SMAD4 在多种癌症中都存在不同程度的失活；本研究旨在探讨非小细胞肺癌（NSCLC）中 SMAD4 表达与临床病理参数的相关性。
方法
通过酶联免疫吸附试验（ELISA）测定 SMAD4 的血清浓度，并通过免疫组织化学定量其组织表达。
结果
NSCLC 患者血清 Smad4 浓度低于良性肺部疾病患者和健康个体（P<0.001），且其浓度与组织学分类、病理分化、淋巴转移和 NSCLC 临床分期相关。血清 Smad4 筛查健康个体 NSCLC 的灵敏度和特异性分别为 91.56%和 61.56%，筛查良性肺部疾病患者 NSCLC 的灵敏度和特异性分别为 84.55%和 60.36%。Logistic 回归分析表明，细胞分化程度（P<0.001）、淋巴结转移（P<0.001）和 NSCLC 临床分期（P=0.007）影响 Smad4 的表达，且与 Smad4 的表达具有很强的相关性。NSCLC 组织中 Smad4 的表达低于正常肺组织（P=0.009），其表达与组织分化程度、淋巴结转移和临床分期相关（P<0.05）。
结论
Smad4 的下调或缺失与 NSCLC 的恶性生物学行为有关，血清 Smad4 可作为 NSCLC 诊断和评估的潜在分子指标。
Zotero 插件